Whalesbook
Metropolis Healthcare Ltd.'s stock surged over 6% on Monday, a reaction to the company's third-quarter financial update which reported a significant 26% year-on-year jump in standalone revenue for Q3 FY26. This strong performance ignited investor optimism, propelling the healthcare services firm's shares to their highest level since early November 2025.
The company's shares reached their highest point since November 6, 2025, marking the biggest intraday gain since October 6, 2025. As of 1:10 PM, the stock was trading 4.5% higher, significantly outperforming the Nifty 50's marginal 0.03% decline. This rally propelled Metropolis Healthcare's market capitalization to ₹10,439.80 crore.
Robust Growth Metrics
The company detailed strong performance across segments. It announced a 26% year-on-year growth in consolidated revenue. This was driven by sustained momentum in preventive and wellness health check-ups under the TruHealth brand and a sharp rise in specialty testing volumes. The B2C segment contributed with an 18% year-on-year revenue increase, while the B2B segment saw substantial growth of approximately 37%. On a standalone basis, revenue grew by about 15% year-on-year, supported by higher patient and test volumes.
Segment Performance Highlights
Within the TruHealth wellness and specialty segments, year-on-year growth figures reached approximately 35% and 33%, respectively. The integration of recent acquisitions is also progressing well, contributing to operational efficiencies and improved profitability.
Market Context
Metropolis Healthcare's recent performance contrasts with its standing over the past 12 months, during which its stock had fallen 1.4%, compared to the benchmark Nifty 50's 11% advance. The company's market capitalization currently stands at ₹10,439.80 crore.